Oxonica Share Discussion Threads

[damanko] 04/3/2007 09:17

Not sure is the quick answer. The Oxonica website should tell you. Failing which, an email or telephone call to the company is usually responded to quickly.

[hyper al] 03/3/2007 22:59

Concerning last years Nanoplex agreement with BD.

Is BD using Nanoplex in any of its products?

[hyper al] 03/3/2007 22:43

The more I research, the more I like!

[hyper al] 03/3/2007 22:29

Like the technology, going on my watch list.

[matt7777] 28/2/2007 11:39

looks like some trades going through at 130p, anyone know if they would have been earlier sells, reported late, or new buyers having to pay outside the current spread ?? cheers

[nod] 09/2/2007 22:41

That's a fairly hefty dilution of 2m shares coming up. Has there been any news recently on how the Nanoplex acquisition has fared? I don't think Nanoplex was mentioned in the trading update.

[waldron] 09/2/2007 15:46

Oxonica Deferred Considerations


RNS Number:0447R
Oxonica plc
09 February 2007



For immediate release 9 February 2007

OXONICA PLC

Acquisition of Nanoplex Technologies Inc

Payment of Deferred Consideration

Oxonica plc (Oxonica), a leading international nanomaterials group, today
announces that, further to the announcements made on 20 December 2005 and 8
February 2006, the Board confirms that the final outstanding conditions in
connection with the acquisition of Nanoplex Technologies Inc ("Nanoplex") have
now been satisfied.

Under the terms of the acquisition agreement, deferred consideration of up to
1,338,366 new ordinary shares were to be issued during the 18 months after
completion contingent on the achievement of certain milestones, together with
751,644 shares issued 12 months after completion subject to there being no
claims under Nanoplex's representations and warranties. Completion of the
Nanoplex acquisition occurred on 8 February 2006.

Application has been made to the London Stock Exchange for 2,090,005 new
ordinary shares in Oxonica to be admitted to trading on AIM on 16 February 2007.
The 2,090,005 new ordinary shares will, upon issue, rank pari passu with the
Company's existing issued ordinary shares. The 2,090,005 new ordinary shares are
subject to an orderly market agreement which expires on 19 July 2007.


For further information:

Oxonica plc 01865 856 700
Kevin Matthews, Chief Executive Officer
Richard Clarke, Chief Financial Officer

Panmure Gordon & Co 020 7459 3600
Hugh Morgan
Andrew Potts

Smithfield 020 7360 4900
George Hudson



NOTES TO EDITORS

About Oxonica plc - www.oxonica.com

Oxonica (AIM: OXN.L) is one of the leading International nanomaterials groups
with products already launched into international markets and is listed in
London on the AIM market. It was spun-out from Oxford University in 1999 and
currently employs 56 professional staff. Oxonica's mission is to focus on the
development of innovative commercial solutions for international markets using
its expertise in the design and application of nanomaterials. It owns a
portfolio of demand driven products that offer substantial benefits to the
target markets of energy, healthcare, materials and security.

The Group currently has four operating divisions: Oxonica Energy, Oxonica
Healthcare, Oxonica Materials and Oxonica Security. Oxonica has already
launched products into international markets. Lead products include:

* Envirox(TM) Fuel Borne Catalyst - a nanocatalyst improving fuel economy and
reducing emissions

* Optisol(TM) UV Absorber - a revolutionary photostable UV protection system
designed to optimise the performance of quality sunscreens and anti-premature
aging products

Oxonica is also active in searching for the next generation of products and is
already engaged in developing transformational detection technologies which
will enable a new generation of ultrasensitive multiplex diagnostic tools for
the clinical diagnostic life science and security markets. In addition, the
company is developing other UV absorber technologies into polymer systems and
coatings, based on similar technologies to that used in Optisol(TM).

- Ends -



This information is provided by RNS
The company news service from the London Stock Exchange

END
LISILFVEFIIAIID

[taylor20] 08/1/2007 15:48

Received by email today, think I cut & pasted the whole of the email

[johnpeart] 08/1/2007 15:00

Taylor

Was there a date on this publication you have posted?

[taylor20] 08/1/2007 13:47

FWIW

Buy Oxonica at 143.5p
Says Rebecca Turner,
editor of AIM and Plus Newsletter
Oxonica is an international nanomaterials group with two products in the market. The first, Envirox, is a fuel borne nanocatalyst for diesel engines which reduces fuel consumption with savings of 5-10%. Particulate emissions are reduced by up to 15%. It has already been adopted by Stagecoach in the UK and is distributed by DMX Technology to petroleum companies in the Philippines for use in a premium diesel. The second product, Optisol, is a photostable UV absorber that provides enhanced and longer-lasting protection against UVA in sun care and anti ageing products. It also reduces the formation of free radicals produced from exposure to the sun and which are implicated in premature skin ageing. Boots was the first to incorporate Optisol in its Soltan range in 2005.

Oxonica is also working on its future range of product applications. These include fuel saving additives, market technology for the clinical and life science diagnostics markets, further UV protection applications (including tailoring Optisol in the cosmetics markets), and new products for plastics and coatings, transparent conducting films and security markers. Nanotechnology has the potential to bring benefits to many aspects of product application, in areas as diverse as drug development, energy and environment, information and communications technologies and the production of stronger, lighter materials.

The company has four operating divisions: Energy, Healthcare, Materials and Security to exploit this potential. Oxonica made solid progress in the first calendar half of 2006. It completed the acquisition of Nanoplex Technologies, negotiated a key supply contract for Envirox, and sealed a licence with a global medical technology firm. On top of these milestones, it also achieved ISO 9001 accreditation. The numbers were equally positive.


Oxonica reported an 87% rise in revenues to 1.3 million pounds with gross profits more than doubling to 0.77 million pounds. An operational loss of 3.1 million pounds was incurred, pushed higher by greater development, sales and admin costs associated with Nanoplex. The group finished the period with cash of 2.8 million pounds.

The Envirox supply contract was signed with Turkey's largest oil company, Petrol Ofisi, and is worth an initial $12.7 million in the second half. This first run will be used to evaluate market acceptance of its new enhanced fuel. The success will be mostly down to Ofisi's marketing ability, although it has grown its market share in recent years since privatisation and clearly wants to differentiate its fuel offering. What is more, diesel accounts for more than half the fuel market in Turkey. So while the deal significantly boosts current year revenues, there is greater potential on an ongoing basis. This deal has had a major impact on analyst forecasts and indicates the scale benefits of the business. For calendar 2006, Oxonica should deliver revenues of 9.1 million pounds (up from original expectations of just 2.4 million pounds) which will take the company into a second half profitability of 1 million pounds but an overall full year loss of 1.8 million pounds.

*This email represents the views of UK-Analyst and are not the views of IG Index. Remember that spread betting is a leveraged product and can result in losses that exceed your initial deposit. It may not be suitable for everyone, so please ensure that you fully understand the risks involved. The value of investments can go down as well as up. Investing in equities can lose you part or all of your capital. Smaller company shares can be relatively illiquid and thus hard to trade. And that makes such investments more of a high risk than larger company shares. Aimnewsletter.co.uk is owned by t1ps.com, which is authorised and regulated by the FSA and can be contacted at 3rd Floor, Henry Thomas House, 5 - 11 Worship Street, London EC2A 2BH or 02075623370.

In 2007, revenues are projected to reach 13.9 million pounds, which will lead to profits of 0.4 million pounds and earnings of 0.9p. Revenues will further scale up in 2008 to 21.4 million pounds, generating profits of 4.6 million pounds and earnings of 7.9p. Thus the shares trade on a two-year multiple in the high teens. Oxonica is likely to continue licensing-in some of its technology from universities, which do not have the commercial expertise and resource to take a product to market. The company is the one of the UK's few pure nanotechnology plays, and while the free float is limited to around 8%, we expect further funds will be raised for R&D and expansion as its products reach the mass market. As more Envirox and Optisol sales are secured, the company will enjoy stronger visibility and profitability to generate shareholder returns and re-invest in new areas of development.

While it is difficult to predict the timing and scale of similar agreements like Ofisi, this forms the basis of just one of the four divisions, and the potential upside is vast. A SPECULATIVE BUY.

Key Data

EPIC: OXN
Spread: 140 - 147
Market: AIM

[grupo guitarlumber] 15/10/2006 08:27

MIDAS SHARE TIPS
Oxonica: small but perfectly formed

8 October 2006

Say 'nanotechnology' and many of us would go scurrying for a dictionary.

A few would recognise the term as referring to the technology of extremely smallscale materials or mechanisms.
For investors it means a small but fascinating opportunity.

Nanotechnology is more than science fiction. It is a reality and the paramount example on the London stock market is Oxonica.

A spin-off from Oxford University, Aim-listed Oxonica may not be a household name, but there is a good chance that you have one of its products on your bathroom shelf without even knowing it.

If you have ever bought Boots' Soltan or Tesco's Finest sun creams, you are an indirect customer of Oxonica, which provides its Optisol product to both companies.

Optisol is a nanotechnology product, a highly complex material built up molecule by molecule-that acts as a defence against UVA radiation - sunlight that does not actually burn you red, but which nevertheless is a cause of skin cancer.

Popular knowledge of sun screens centres on the SPF level, but this refers only to UVB protection. Growing awareness of

the dangers of UVA is expected to increase demand for products like Optisol.

Another application for Oxonica's products is fuel efficiency. Envirox is a complex molecule which, when added in minute quantities to diesel, cuts carbon emissions and it makes the fuel more efficient.

In August, Envirox was adopted by Petrol Efisi, the leading oil company in Turkey. From now on, lorry drivers in Turkey will get more miles per gallon and pollute less. British bus company Stagecoach has also adopted the fuel additive.

It is thought that large oil groups are looking at Envirox. Should a company like Shell or BP adopt Envirox, the boost to Oxonica would be dramatic. But even without this, the group is on the path to success.

The Efisi deal is expected to create sales of about £8 million a year, a massive jump for a company whose turnover last year was only £1.28 million.

The deal also means that it will report its first profit for the second half of 2006.

Oxonica has several other products up its sleeve, but these two alone indicate this is not just another speculative technology company but a business with real commercial potential.

Among those who agree is Richard Farleigh, the millionaire private-investor best known as one of the BBC's Dragons' Den panel, who has a 17 per cent stake.

••Midas verdict: Oxonica is not cheap. Its shares had been sliding until the Efisi deal sparked a jump. They are now 140p and earnings are forecast to hit just 1p a share in 2007. But what Oxonica has going for it are proven products at the start of their commercial life.

[majago] 09/10/2006 12:55

Thanks Gardener

[gardener1] 09/10/2006 09:27

Positive article in the Mail on Sunday - heading "Oxonica: small but perfectly formed".
"For those willing to take a risk for the long term, Oxonica looks appealing. Like it's technology it is small but it's potential is huge. Buy "

[majago] 09/10/2006 09:08

Not that i'm complaining but has anyone got any ideas as to the reason for the rise this morning?

[s_merryfield] 24/9/2006 15:32

Oxonica

Warren Buffet famously said he would not invest in companies he did not understand. For that reason, investors who do not have a doctorate in nanotechnology might take the Sage of Omaha's advice and give , which commercialises materials made up of minute particles, a wide berth.

The company was spun-out of the University of Oxford in 1999 in order to turn wizzy nanotechnology ideas into commercial success stories. Seven years and millions of pounds of losses later, analysts believe Oxonica will finally turn a profit by the end of the year. Oxonica had two pieces of good luck. First, softly spoken Dragon's Den guru Richard Farleigh took an early interest, beginning with an initial £300,000 investment at the time Oxonica was spun-out of Oxford, rising to £5m.

Secondly, in 2001, former academic Dr Kevin Matthews was hired to sharpen up Oxonica's act and make it more palatable to the business community. Oxonica's chief executive does have a doctorate from Oxford and so can easily understand what the company does, but he also left academia early in his career to cut his teeth in the private sector. As a result, Oxonica got the required commercial focus it needed. Mr Farleigh took an enormous punt and made a handsome return, something Questor does not begrudge him given the risk he took, but the question new investors must ask today is what upside remains?

The answer is: potentially an awful lot. Certainly enough to warrant a punt, particularly as the risk has reduced significantly since Mr Farleigh first entered the fray. Oxonica's major commercial breakthrough came in August when it announced a deal to supply Turkish oil company Petrol Ofisi with its new green technology, Envirox. Already used by Stagecoach, Envirox is added to diesel and boosts fuel efficiency by 5pc to 11pc, while reducing carbon dioxide emissions. Ten other oil companies are believed to be studying the technology. If it proves successful, Oxonica will have broken into what Panmure Gordon analyst Mark Davis estimates might be a £1bn market.

Another Oxonica success, Opitsol, is added to sun creams to increase the length of time they protect skin from ultra-violet rays. Boots started using it in its Soltan cream in 2005 and is already coming back for more.

Risks remain: the company is small, with a market value of £54m, and relies on cutting edge technologies, but even Buffet must admit there is clear commercial potential in what Oxonica is doing. At a recent price of 130p, Oxonica's shares are a buy.

Source:

[chippy2] 22/9/2006 07:17

Tipped in IC today.

[damanko] 22/8/2006 10:31

May provide a temporary floor for the shares, lock in agreement standard.